Piramal Pharma

37
Sell
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0DK501011
  • NSEID: PPLPHARMA
  • BSEID: 543635
INR
209.40
1.1 (0.53%)
BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 50.67 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Operating Income
8,869.00
9,151.00
8,171.00
7,081.00
6,559.00
6,314.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
8,869.00
9,151.00
8,171.00
7,081.00
6,559.00
6,314.00
Expenditure (Ex Depriciation)
Stock Adjustments
-187.00
-241.00
-198.00
68.00
55.00
-52.00
Raw Materials Consumed
3,426.00
3,473.00
3,152.00
2,634.00
2,396.00
2,111.00
Power & Fuel Cost
260.00
267.00
241.00
207.00
163.00
136.00
Employee Cost
2,415.00
2,307.00
2,029.00
1,896.00
1,588.00
1,467.00
Operating Expenses
630.00
607.00
571.00
531.00
460.00
445.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
431.00
392.00
352.00
369.00
317.00
250.00
Cost of Software developments
56.00
42.00
31.00
30.00
0.00
0.00
Miscellaneous Expenses
224.00
187.00
152.00
166.00
71.00
68.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
7,947.00
7,706.00
6,974.00
6,453.00
5,609.00
4,886.00
Operating Profit (PBDIT) excl Other Income
921.00
1,444.00
1,196.00
628.00
949.00
1,427.00
Other Income
213.00
134.00
175.00
225.00
275.00
164.00
Operating Profit (PBDIT)
1,134.00
1,579.00
1,371.00
853.00
1,225.00
1,592.00
Interest
340.00
421.00
448.00
344.00
198.00
163.00
Profit before Depriciation and Tax
794.00
1,158.00
923.00
509.00
1,027.00
1,428.00
Depreciation
831.00
816.00
740.00
676.00
586.00
545.00
Profit Before Taxation & Exceptional Items
-37.00
341.00
182.00
-167.00
441.00
883.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
-176.00
414.00
179.00
-120.00
484.00
949.00
Provision for Tax
149.00
323.00
161.00
66.00
109.00
114.00
Profit After Tax
-383.00
18.00
-41.00
-240.00
316.00
787.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
1,049.00
970.00
956.00
1,158.00
832.00
835.00
Profit Available for appropriations
723.00
1,061.00
974.00
972.00
1,208.00
1,670.00
Appropriations
723.00
1,061.00
974.00
972.00
1,208.00
1,670.00
Equity Dividend (%)
0.00%
1.40%
1.10%
0.00%
0.00%
0.00%
Earnings Per Share
-2.46
0.69
0.14
-1.54
3.19
13.30
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2026 is -3.08% vs 11.99% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2026 is -36.21% vs 20.78% in Mar 2025

stock-summary

Interest

YoY Growth in year ended Mar 2026 is -19.16% vs -6.00% in Mar 2025

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2026 is -2,205.16% vs 143.68% in Mar 2025

Compare Profit and Loss Results of Piramal Pharma
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
8,869.00
1,694.00
7,175.00
423.55%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
8,869.00
1,694.00
7,175.00
423.55%
Expenditure (Ex Depriciation)
Stock Adjustments
-187.00
4.00
-191.00
-4,775.00%
Raw Materials Consumed
3,426.00
460.00
2,966.00
644.78%
Power & Fuel Cost
260.00
48.00
212.00
441.67%
Employee Cost
2,415.00
549.00
1,866.00
339.89%
Operating Expenses
630.00
94.00
536.00
570.21%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
431.00
11.00
420.00
3,818.18%
Cost of Software developments
56.00
0.00
56.00
0%
Miscellaneous Expenses
224.00
35.00
189.00
540.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
7,947.00
1,286.00
6,661.00
517.96%
Operating Profit (PBDIT) excl Other Income
921.00
407.00
514.00
126.29%
Other Income
213.00
36.00
177.00
491.67%
Operating Profit (PBDIT)
1,134.00
444.00
690.00
155.41%
Interest
340.00
78.00
262.00
335.90%
Profit before Depriciation and Tax
794.00
366.00
428.00
116.94%
Depreciation
831.00
138.00
693.00
502.17%
Profit Before Taxation & Exceptional Items
-37.00
227.00
-264.00
-116.30%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
-176.00
227.00
-403.00
-177.53%
Provision for Tax
149.00
57.00
92.00
161.40%
Profit After Tax
-383.00
170.00
-553.00
-325.29%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
1,049.00
553.00
496.00
89.69%
Profit Available for appropriations
723.00
723.00
0.00
0.00%
Appropriations
723.00
723.00
0.00
0.00%
Equity Dividend (%)
0%
0%
0.00
Earnings Per Share
-2.46
8.83
-11.29
-127.86%
Profit And Loss - Net Sales
Net Sales 8,869.08 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -3.08% vs 11.99% in Mar 2025

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 921.62 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -36.21% vs 20.78% in Mar 2025

Profit And Loss - Interest
Interest 340.80 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -19.16% vs -6.00% in Mar 2025

Profit And Loss - Profit After Tax
Profit After Tax -383.14 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -2,205.16% vs 143.68% in Mar 2025